Le Lézard
Classified in: Health
Subjects: MAV, POL, FVT, CFG

Notice to the media - Government of Canada to announce funding to help eliminate HIV/AIDS in Labrador


HAPPY VALLEY-GOOSE BAY, NL, March 12, 2018 /CNW/ - On behalf of the Honourable Ginette Petitpas Taylor, Minister of Health,  Yvonne Jones, Member of Parliament for Labrador and Parliamentary Secretary to the Minister of Crown-Indigenous Relations and Northern Affairs will announce federal support to eliminate HIV/AIDS

Date
March 13, 2018

Time
2 P.M.

Location
Mokami Status of Women Council
43 Grenfell Street
Happy Valley - Goose Bay
NL A0P 1E0

 

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 06:50
U.S. FDA Approves Pfizer's BEQVEZtm (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
CENTENE CORPORATION REPORTS FIRST QUARTER 2024 RESULTS
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor® Reports First Quarter 2024 Results
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

More news about Health...


News published on and distributed by: